

File reference	W18FOI645
Key words	Request regarding the use of the new biosimilar biologic therapies
Date of release	01/04/2019
Attachments	Yes

Freedom of Information Act Disclosure log - Reply Extract

You asked

This is a freedom of information request relating to the use of the new biosimilar biologic therapies.

1. Does your trust use the following biosimilar biologic therapies, and if possible how many patients are currently being treated?

Adalimumab [Hyrimoz] = No

Adalimumab [Amgevita] = Yes - Five or fewer

Adalimumab [Imraldi] Yes - Five or fewer

Adalimumab [Hulio] = No

Etanercept [Benepali] = Please refer to the attached spreadsheet noting that the Trust has not yet published quarter four data, but intends to do so in the future. It currently considers the last quarter's data exempt from supply in accordance with section 22.-(a) - Information intended for later publication at a future date. The information will be published here:

<https://www.plymouthhospitals.nhs.uk/corporate-services-information>

Our rationale is described on the spreadsheet.

Any data involving numbers of five or fewer patients are and will be considered exempt from supply in accordance with section 40.-(2)(a) and (b) by virtue of the first and second condition. This avoids a breach of the first two Data Protection Act principles and the general right to object to processing.

Due to technical constraints, the Trust is unable to upload the attachment relating to this request. To obtain this, please email plh-tr.FOI-requests@nhs.net quoting the file reference.

Etanercept [Erelzi] = No

Infliximab [Inflectra] = As per our response to Etanercept(Benepali)

Infliximab [Remsima] = As per our response to Etanercept(Benepali)

Infliximab [Flixabi] = As per our response to Etanercept(Benepali)

2. Within your rheumatology department;
 - a. how many patients in the year 2018 were treated with a biologic or JAK2

b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

Hydroxychloroquine: Five or fewer patients

- 3. Within your dermatology department;**
a. how many patients in the year 2018 were treated with a biologic or JAK2
b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

Ciclosporin: Five or fewer patients

- 4. Within your gastroenterology department;**
a. how many patients in the year 2018 were treated with a biologic or JAK2
b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

Nil

- 5. Does your trust record the DAS score electronically on the patient records?, If so how many are DAS 5+ No/Yes [if Yes number]**

The Trust did not receive the clarification necessary to process this part of your request. We will process this part separately upon receiving your response to our earlier email dated 18.03.2019.

Legal notes

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles and the general right to object to processing. This refusal is in accordance with section 40.-(2)(a) and (b) by virtue of the first and second condition. It also satisfies our duties in compliance with section 16 of the FOI to offer advice and assistance.

Section 22 notes are provided in the body of the reply.

Attachments included: No